Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLS-002 in MDD at Imminent Risk of Suicide
NCT04669665Phase 2Completed
- Sponsor
- Seelos Therapeutics, Inc.
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SLS-002 in major depressive disorder (MDD), sponsored by Seelos Therapeutics, Inc.. Started Dec 2020; status: completed.
02
Drugs
SLS-002
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04669665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669665.